The phase III ATLAS trial demonstrated improved progression-free survival with atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-rearranged or -translocated NSCLC who had progressed with TKI therapy [125]. Here, ALK is linked to non-small cell lung carcinoma.